About Enterobiotix
Enterobiotix is a company based in Edinburgh (United Kingdom) founded in 2017. Enterobiotix has raised $72.96 million across 10 funding rounds from investors including Syndicate Room, Scottish Enterprise and NCIMB. The company has 65 employees as of December 31, 2023. Enterobiotix offers products and services including EBX-102-02 and IMT Therapies. Enterobiotix operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 65 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enterobiotix Limited
- Date of Incorporation 02 Mar, 2017
- Jurisdiction GLASGOW, SCOTLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$72.96 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
-
Investors
Syndicate Room
& 11 more
-
Employee Count
65
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enterobiotix
Enterobiotix offers a comprehensive portfolio of products and services, including EBX-102-02 and IMT Therapies.
Treatment for irritable bowel syndrome via gut restoration
Therapies to restore and enhance gut microbial ecology
People of Enterobiotix
Unlock access to complete
Unlock access to complete
Funding Insights of Enterobiotix
Enterobiotix has successfully raised a total of $72.96M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enterobiotix
Enterobiotix has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Syndicate Room, Scottish Enterprise and NCIMB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on social impact companies
|
Locked | Locked | Locked | |
|
Angel investment funding is facilitated for early-stage Scottish businesses.
|
Locked | Locked | Locked | |
|
Early-stage investment is provided to promising Scottish entrepreneurs.
|
Locked | Locked | Locked |
Investor details for Enterobiotix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enterobiotix
Investment portfolio details for Enterobiotix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enterobiotix
Detailed financials for Enterobiotix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enterobiotix Comparisons
Peer comparison for Enterobiotix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enterobiotix
Enterobiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal diseases are developed and provided.
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
Detailed competitors of Enterobiotix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enterobiotix
Complete news archive for Enterobiotix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enterobiotix
Enterobiotix was founded in 2017.
Enterobiotix is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Enterobiotix is a funded company, having raised a total of $72.96M across 10 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Enterobiotix is 65.
Enterobiotix was founded in 2017 in Edinburgh, United Kingdom, within the biotechnology sector. Focus is placed on microbiome-based therapeutics targeting multiple diseases, especially those affecting the gut like Inflammatory Bowel Disease. An integrated anaerobic system is under development, featuring a closed benchtop setup for collection and processing that supports therapy production in anaerobic conditions without cleanrooms. Operations aim to deliver these treatments to patients through controlled, non-sterile environments.
Enterobiotix's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Enterobiotix offers EBX-102-02 and IMT Therapies.
Enterobiotix has 12 investors. Key investors include Syndicate Room, Scottish Enterprise, NCIMB, University of Aberdeen, and Kineticos.